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Objective. Premature complexes (PCs) in the electrocardiogram (ECG) signal have been reported for
myocardial contrast echocardiography and also for burst mode (physical therapy) ultrasound with gas
body contrast agents at lower peak rarefactional pressure amplitudes (PRPAs). For contrast echocar-
diography, irreversibly injured cardiomyocytes have been associated with the arrhythmia. The objective
was to determine whether cardiomyocyte injury is associated with the PCs induced by the burst mode
at lower PRPAs. Methods. Anesthetized rats were exposed to focused 1.5-MHz ultrasound in a water
bath. Evans blue dye was injected intraperitoneally to stain injured cardiomyocytes, and a perflutren
lipid microsphere ultrasound contrast agent was infused intravenously. The continuous burst mode
simulated physical therapy ultrasound. Intermittent 2-millisecond bursts, or envelopes of pulses simu-
lating diagnostic ultrasound, were triggered 1:4 at end systole. Premature complexes were observed
on ECG recordings, and stained cardiomyocytes were counted in frozen sections. Results. The contin-
uous burst mode produced variable PCs and stained cells above a 0.3-MPa PRPA. The triggered bursts
above 0.3 MPa and pulse envelopes above 1.2 MPa produced statistically significant (P < .01) PCs and
stained cardiomyocytes. Conclusions. Irreversible cardiomyocyte injury was associated with the devel-
opment of PCs for the burst mode and occurred at substantially lower PRPAs than for pulsed ultra-
sound. Key words: arrhythmia; contrast agent adverse effects; gas body activation; myocardial
contrast echocardiography; ultrasonic cavitation biology.
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ltrasound contrast agents are approved for use
in enhancing diagnostic ultrasound images.
The agents consist of suspensions of gas bod-
ies (stabilized microbubbles), which circulate
in the blood pool and return strong echoes relative to the
weak echoes from blood. The first application of gas body
contrast agents was for echocardiography with approval
to opacify the blood pool within the left ventricular
chamber and to improve the delineation of the endocar-
dial border. Myocardial contrast echocardiography is
another application, which seeks to image perfusion in
the cardiac muscle. This can be accomplished at rela-
tively high pulse peak rarefactional pressure amplitudes
(PRPAs) of diagnostic ultrasound by destroying the gas
bodies and then observing the rate of refill of blood with
fresh gas bodies into the tissue. Safety considerations for
contrast enhanced diagnostic ultrasound have received
substantial research interest because the interaction
between ultrasound pulses and gas bodies is an impor-
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tant mechanism for nonthermal bioeffects of
ultrasound. This research has led to a variety of
bioeffects findings and to potential therapeutic
applications.1
An intriguing bioeffect of myocardial contrast
echocardiography is cardiac arrhythmia. This
effect has been reported in humans2,3 as well as
laboratory animals, including rats4 and dogs.5 The
arrhythmia effect of contrast echocardiography
occurs at relatively high PRPAs, which are also
associated with gas body destabilization and
destruction by the ultrasound pulses. The arrhyth-
mia shows as premature complexes (PCs) in the
electrocardiogram (ECG) signal, which occur coin-
cidentally with the ultrasound image exposure and
cease after the ultrasound is stopped. A typical
exposure that elicits this arrhythmia in rats
involves infusion of a contrast agent, intermittent
imaging every fourth complex (1:4) at end systole,
and a PRPA above about 1 MPa at 1.7 MHz.4 The
intermittent image exposure allows for the refill of
tissue capillaries with blood containing gas bodies,
which are destroyed by each image exposure. The
induction of arrhythmia with a contrast agent in
the circulation also has been observed with low-
power burst mode ultrasound, such as that used
for physical therapy.3 Continuous burst mode (2-
millisecond bursts repeated at 10-millisecond
intervals) exposure at 1 MHz and 0.33 to 0.39 MPa
produced more arrhythmia than intermittent (1:4)
1.7-MHz diagnostic ultrasound at 1.0 MPa.
Another important bioeffect at relatively high
PRPAs is irreversible cardiomyocyte injury.
Histologic evidence of cardiomyocyte contrac-
tion band necrosis immediately after exposure
has been shown for diagnostic ultrasound with a
commercial contrast agent in rats.6 Irreversible
cardiomyocyte injury also was identified by
staining with Evans blue dye, which was detected
the day after exposure.7 The incidence of the
Evans blue staining was associated with the
appearance of PCs in the ECG signal used for trig-
gering images, suggesting that the 2 effects were
related. Although the mean numbers of PCs and
stained cardiomyocytes followed a very similar
exposure-response trend with the PRPA, there
was little correlation between the 2 bioeffects for
separate observations in individual animals. This
association was also found for high PRPAs (above
the range of diagnostic ultrasound).8 Premature
complexes were seen for 10 of 20 rats exposed to
3.1-MHz ultrasound with 1.3-microsecond puls-
es at 15.9 MPa and a perflutren protein micro-
sphere contrast agent (Optison; GE Healthcare,
Milwaukee, WI) in the circulation. Myocardial
degeneration was identified by histologic stain-
ing in 16 rats, which implies that the presence of
myocardial degeneration alone may not be a suf-
ficient explanation for the PCs.
The association of arrhythmia and cardiomy-
ocyte injury at moderate and high PRPAs suggests
that the ultrasonic activation of the gas bodies
nucleates cavitation, which induces both bioef-
fects. Cavitation is the most effective mechanism
for nonthermal bioeffects of ultrasound. Cavitation
nucleation by ultrasound contrast agents is impor-
tant in regard to the bioeffects potential in vivo
because there normally are few, if any, cavitation
nuclei in the body suitable for direct activation by
diagnostic ultrasound pulses.9 Ultrasound contrast
agents can supply such nuclei. For example, direct
evidence of cavitational activity has been obtained
by detection of broadband noise emissions from the
myocardium during contrast echocardiography.10
However, this picture is confused by the observation
of PCs with lower-amplitude physical therapy ultra-
sound.3 The objective of this study was to explore
the association between arrhythmia and car-
diomyocyte injury by comparing these effects for
continuous burst mode ultrasound, triggered
single bursts, and square or ramped envelopes of
ultrasound pulses (simulating diagnostic ultra-
sound imaging). A laboratory exposure system
was developed to produce all 3 modes of exposure
under similar conditions (ie, with the same 1.5-
MHz transducer) over a range of PRPAs. Premature
complexes were detected in ECG recordings, and
cardiomyocyte injury was detected by the Evans
blue method. The results strengthen the associa-
tion between the 2 bioeffects of cardiac exposure
to ultrasound with gas body contrast agents.
Materials and Methods
Animal Preparation
All in vivo animal procedures were conducted
with the approval and guidance of the University
Committee on Use and Care of Animals. CD hair-
less rats (Charles River Laboratories, Wilmington,
MA) were anesthetized by intraperitoneal injec-
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tion of a mixture of ketamine (87 mg/mL) and
xylazine (13 mL/kg). A 24-gauge cannula was insert-
ed into a tail vein for intravenous injections. Evans
blue dye in saline (20 mg/mL) at a dose of 100
mg/kg was injected intraperitoneally as a vital stain
for cardiomyocytes. The rats then were mounted
on a holding board, and ECG needle electrodes
were placed in the forelegs and right hind leg. The
holding board was then mounted in a 37°C
degassed water bath for ultrasound exposures.
The ECG signal was amplified (ECGA amplifier;
Hugo Sachs Electronik, March, Germany) and
sent to an oscilloscope (TDS 520B; Tektronix, Inc,
Beaverton OR) and a digitizer (Powerlab 4/30;
ADInstruments, Inc Colorado Springs, CO). 
The digitized ECG was analyzed with the aid 
of software (Chart Pro 5, version 5.5.5;
ADInstruments, Inc), which provided automated
collection of data on the heart rate and numbers of
normal complexes. The software also partially
automated detection of PCs. However, visual
examination of the PCs was performed to classify
these into 2 categories.11 Supraventricular prema-
ture complexes (SPC) including a P wave were
seen with or without a compensatory pause.
Premature ventricular complexes (PVCs) without a
P wave but always with a compensatory pause
were seen singly or followed by reentry complexes.
Definity (Lantheus Medical Imaging, Inc, North
Billerica, MA), a perflutren lipid microsphere
ultrasound contrast agent, was prepared fresh
each day. For infusion, the agent first was diluted
50:1 in sterile saline in a 3-mL syringe, which was
then used to fill a 30-cm extension tube for con-
nection to the tail vein cannula. The syringe was
mounted in a syringe pump (11 Plus; Harvard
Apparatus, Holliston MA), and the infusion rate
was set to 500 µL/kg/min for the diluted agent
(10 µL/kg/min undiluted). Infusions with expo-
sure were 5 minutes in duration. The total agent
dose of 50 µL/kg was about 2.5 times the recom-
mended (package insert) human infusion dose
for diagnostic imaging. 
Ultrasound Exposure
Ultrasound exposure was provided by a labora-
tory system with guidance by diagnostic ultra-
sound imaging, as described previously.12 The
laboratory exposure system consisted of a
transducer, power amplifier (A-500; Electronic
Navigation Industries, Rochester, NY), function
generator for generating a pulse train (3314A;
Hewlett-Packard Company, Palo Alto, CA), and
an arbitrary waveform generator (33220A;
Agilent Technologies, Loveland, CO). The func-
tion generator was set to provide a 1.5-MHz con-
tinuous signal or a pulse train with 3 cycle pulses
and a 230-microsecond pulse repetition period.
The arbitrary waveform generator was used for
amplitude modulation of the continuous or
pulsed signals. Four different signals were pro-
duced: continuous burst (2 milliseconds on, 6
milliseconds off), triggered single bursts 
(2 milliseconds), triggered pulse envelope (2-
millisecond square envelope), and triggered
ramped pulse envelopes (50-millisecond enve-
lope ramping either up or down). The continu-
ous burst simulated the therapeutic ultrasound
mode commonly used for physical therapy. The
triggering was used to allow intermittent expo-
sure timed from the ECG. The triggered pulse
envelope was used to partly simulate intermit-
tent diagnostic ultrasound imaging. Finally, the
ramp-modulated pulses were used to induce or
suppress gas body activity within the tissue, as
described previously.12 Triggering was set at end
systole from the ECG signal displayed on the
oscilloscope by the delayed trigger function. The
oscilloscope delayed trigger out signal was used
to externally trigger the arbitrary waveform gen-
erator to generate the amplitude modulation
envelopes for the function generator. In addi-
tion, the modulation signal was digitized, and
the number of triggers during exposure was
obtained with the Chart Pro software.
A damped single-element transducer (Panametrics
A3464, Olympus NDT, Inc, Waltham, MA) with a
1.9-cm diameter and a 3.8-cm focus was used for
ultrasound exposure. The PRPA of each signal was
measured with a calibrated hydrophone (805;
Sonora Medical Systems, Inc, Longmont, CO). 
The 3-cycle pulse signals produced 1.8-microsec-
ond ultrasound pulses. A diagnostic ultrasound
machine (VingMed System 5; GE Healthcare,
Cincinnati, OH) was used to image the heart with
an 8-MHz probe before exposure. Once an image
of the rat heart that showed a clear path to the
heart was obtained, the exposure transducer was
moved into the same position to aim at the left
ventricle.
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For evaluation of Evans blue staining of car-
diomyocytes, the hearts were removed the day
after exposure and cleared of most blood with
heparin and saline. The heart was trimmed and
then frozen in embedding medium (Tissue-Tek
O.C.T. compound; Sakura Finetek USA, Inc,
Torrance, CA) on dry ice. These samples were
stored in a –80°C freezer for later sectioning on a
frozen section microtome. To search for any
stained cardiomyocytes, 10-µm sections were cut
at each 200 µm into the sample, which typically
gave 20 to 24 slides from the exposed central por-
tion of the heart. Each slide was examined with a
microscope using fluorescence illumination to
estimate the number of Evans blue–stained (red
fluorescent) cells. The slide with the most cell
staining was used to obtain a detailed count of
the number of stained cells (SCs) over the entire
section.
The study was conducted in 16 groups of 5 rats
each and 1 group of 4 rats. For the continuous
burst mode, 1 sham group was exposed to 1 MPa,
and 5 groups were exposed to different PRPAs in
the range of 0.25 to 1.0 MPa (in 3-dB steps). For
the triggered single burst mode, 6 groups were
exposed to PRPAs in the range of 0.25 to 1.4 MPa.
For the triggered pulse envelope, 4 groups were
exposed to PRPAs in the range of 1.0 to 2.8 MPa.
Two groups were exposed with the ramped pulse
envelopes with a maximum 2.8 MPa, 1 with the
ramp up (pulse PRPA increasing with time) and 1
with the ramp down (pulse PRPA decreasing with
time). For all groups, the ECG was monitored and
recorded for 1 minute to confirm stable heart
function under anesthesia, and no PCs were
observed during this preexposure period. For
exposure, the infusion was started; the ultra-
sound was switched on; and the ECG was record-
ed for a manually timed period of 5 minutes. The
ultrasound and infusion were then switched off.
The ECG was monitored and recorded for an
additional 5 minutes, during which no PCs were
seen (ie, any ultrasound-induced arrhythmia
ceased with the cessation of ultrasound expo-
sure). Results are reported as mean ± 1 SD or
plotted with SE bars. For statistical analysis, the
Student t test and Mann-Whitney rank sum test,
as appropriate, were used to compare means of
the measured parameters, with statistical signifi-
cance assumed at P < .05. 
Results
The different types of PCs are shown in Figure 1.
The number of PCs are shown in Figure 2 for 1.0-
MPa continuous burst and triggered single burst
exposures. The SPCs were primarily seen in the
continuous burst mode with none occurring in
the triggered burst mode. Premature ventricular
complexes were the predominant arrhythmias
for the triggered single burst and triggered pulse
envelope exposures. PVCs had both positive and
negative excursions of varying magnitudes. The
PCs began at the point of the triggered exposure
with a delay of about 15 to 20 milliseconds to the
peak of the complex.
The exposure responses of the 2 bioeffects are
shown in Figure 3 for the continuous burst, Figure
4 for the triggered single bursts, and Figure 5 for
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Figure 1. Examples of PCs seen with contrast-enhanced ultra-
sound exposures in 1-second segments of ECG data (arbitrary 0
time start): a, SPC (arrow) without a compensatory pause; 
b, SPC (arrow) with a compensatory pause after the complex; 
c, PVC with positive excursion and a compensatory pause; 
d, PVC with negative excursion and a compensatory pause; e,
PVC followed by reentry and a compensatory pause. The con-
tinuous burst mode at 0.5 MPa was used for a and b. For c–e,
the triggered single burst mode was used, with the exposure
time indicated by the vertical bars.
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the triggered pulse envelope. For all 3 modes,
both effects were essentially 0 and then rose
steadily at higher PRPAs. For the continuous
burst mode, the SC count was small and variable,
with SCs observed in 3 of 5 rat heart samples at
0.35 MPa, 2 of 5 at 0.5 MPa, and 3 of 4 at 0.7 MPa.
The count achieved statistical significance only
at the 1.0-MPa level. However, the PCs were
observed for all rats exposed at and above 0.35
MPa. The PCs were statistically significant at 
0.35 MPa, which indicates a threshold at 0.3 MPa
(midway between the lowest level with a signifi-
cant effect and the highest level without a sig-
nificant effect). The exposures triggered from the
ECG, which allowed refill of blood containing
contrast agent gas bodies, produced much
larger counts of PCs and SCs. For the triggered
single bursts, both effects were not statistically
significant at 0.25 MPa but were at 0.35 MPa,
indicating a threshold of 0.3 MPa for both bioef-
fects. For the triggered pulse envelope, both bio-
effects were significant at 1.4 MPa but not at 1.0
MPa, indicating thresholds of 1.2 MPa. Modes
and thresholds are listed in Table 1.
The trends in the data for all 3 modes seem to
be very similar for both the PCs and SCs. Results
for the 2 effects were examined by linear regres-
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Figure 2. Numbers of PCs resembling Figure 1, a and b, and
PVCs resembling Figure 1, c–e, for the continuous burst and
triggered single burst modes at 1.0 MPa. Premature ventricular
complexes were the predominant PCs in the triggered mode.
Figure 4. Means with SE bars for the numbers of PCs and Evans
blue–stained SCs found for the triggered burst mode. The results
were much greater than for the continuous burst mode (Figure
3), but again, the data trends with PRPAs are similar for both
effects.
Figure 3. Means with SE bars for the numbers of PCs and Evans
blue–stained SCs found for the continuous burst mode. The
data trends with PRPAs are similar for both effects.
Figure 5. Means with SE bars for the numbers of PCs and Evans
blue–stained SCs found for the triggered pulse envelope mode.
The results are diminished for the pulsed mode relative to the
burst mode (Figure 4), but the data trends with PRPAs remain
similar for both effects.
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sion on the individual data and the means.
Results for the 3 modes are shown in Figures 6–8
with r2 values listed in Table 1. Regression for the
continuous burst mode showed no correlation
between the 2 effects for individual data, which
was highly variable, but good correlation for the
means. For the triggered single burst and pulse
envelope modes, the correlation was good for
both the individual data and the means. The
results for triggered exposure strengthen the
association between these 2 bioeffects.
The results for the ramp envelope exposure are
shown in Figure 9. The ramp-up and ramp-down
envelopes produced a different relative occur-
rence of the 2 bioeffects. The ramp-up condition
produced slightly fewer, but not significantly
fewer, PCs than the ramp-down condition. The SC
counts were reduced significantly (P < .001) for the
ramp-up relative to the ramp-down condition.
Discussion 
Premature complexes in the ECG record have
been reported for ultrasound with a gas body
contrast agent for diagnostic B-mode ultrasound
above about 1.0 MPa and also for the burst mode
at substantially lower PRPAs. For B-mode ultra-
sound, injured cardiomyocytes have been asso-
ciated with PCs. The objective of this study was
to determine whether the PCs seen with burst
mode exposure at lower PRPAs are also associat-
ed with cardiomyocyte injury. Three modes were
used for characterizing the 2 bioeffects versus the
exposure PRPA: a continuous burst (2 millisec-
onds on, 6 milliseconds off), single bursts, and
pulse envelopes both triggered at 1:4 heartbeats
during end systole. All 3 modes produced similar
trends for both bioeffects, which was a steady
increase with PRPAs above an apparent thresh-
old (Figures 3–5). The continuous burst mode
produced somewhat variable results, for which
the 2 bioeffects were not correlated (except for
regression on the means). It seems likely that the
variability resulted from the continuous nature
of the exposure, which might have prevented
refilling of the capillary bed with blood contain-
ing gas bodies. The bioeffects thresholds were
both 0.3 MPa for the triggered burst mode and
both 1.2 MPa for the square pulse envelope
(Table 1). The pulse envelope thresholds were
similar to those found for diagnostic imaging
exposure.7 For burst mode exposure, irreversible
cardiomyocyte injury was induced together with
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Table 1. Apparent Thresholds for PCs and SCs for the 3 Exposure
Modes and Correlation Coefficients for Regression Against
Individual Data and Means 
Threshold, MPa r2
Mode PC SC Data Mean
Continuous burst 0.3 0.85a 0.01 0.87
Triggered single bursts 0.3 0.3 0.72 0.85
Triggered pulse envelope 1.2 1.2 0.85 0.96
Apparent thresholds are defined as the midpoint between the lowest
megapascal level with a significant effect and the next lower level.
aThe SC effect was not statistically significant below 1.0 MPa, but SCs
were observed in 3 of 5 rat heart samples at 0.35 MPa, 2 of 5 at 0.5
MPa, and 3 of 4 at 0.7 MPa.
Figure 6. Linear regressions of the SC and PC counts for the
continuous burst mode. Although the data means (squares, bidi-
rectional error bars, and dashed line) have a good correlation,
the individual data points (circles and solid line) do not (Table 1).
Figure 7. Linear regressions of the SC and PC counts for the
triggered burst mode. Both the data means (squares, bidirec-
tional error bars, and dashed line) and the individual points (cir-
cles and solid line) have a good correlation (Table 1).
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arrhythmia at substantially lower PRPAs than for
pulsed ultrasound. There was a good correlation,
especially for the triggered modes, between the 2
bioeffects (Figures 6–8 and Table 1).
For tests with a ramped pulse envelope, the
ramp-up envelope reduced the cardiomyocyte
injury (P < .001), but the arrhythmia bioeffect
was not statistically different from that for the
ramp-down condition. In previous work, 
the ramp-up envelope essentially abolished the
glomerular capillary hemorrhage effect in rat
kidneys, which was seen with the ramp-down
envelope.12 This mitigation of the capillary hem-
orrhage was thought to be due to the destabiliza-
tion and loss of potentially effective gas bodies
by relatively low-amplitude pulses in the ramp
up, before the suprathreshold pulses arrived (for
the ramp down, the reverse is true). For the car-
diac bioeffects observed in this study, the ramp-
up envelope did not abolish either bioeffect, and
SCs were associated with the occurrence of PCs
even for this bioeffects mitigation mode.
The 2 bioeffects, PCs and injured cardiomyocytes,
induced by intermittent cardiac exposure to
ultrasound with a gas body contrast agent occurred
together, with similar thresholds, exposure-
 response trends, and a good correlation for the low-
PRPA burst mode as well higher-amplitude pulsed
ultrasound. This shows that both bioeffects are
caused by gas body activation, with destabiliza-
tion and nucleation of cavitation, at similar
PRPAs. Irreversible cardiomyocyte injury may be
expected whenever PCs develop from intracar-
diac ultrasonic cavitation activity.
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